2022
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
Yamamoto N, Hafez N, Tolcher A, Teufel M, Geng J, Svensson L, Lahmar M, Gounder M. A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 3095-3095. DOI: 10.1200/jco.2022.40.16_suppl.3095.Peer-Reviewed Original ResearchDose-limiting toxicityImmune checkpoint inhibitorsDoublet combinationsCheckpoint inhibitorsPrimary endpointPhase Ia/Ib studySolid tumorsManageable safety profileMDM2-p53 antagonistsProgression-free survivalAdvanced solid tumorsBiliary tract carcinomaMetastatic solid tumorsSoft tissue sarcomasAnti-tumor effectsWild-type cancersAnti-tumor activityLogistic regression modelsPhase IaMultiple tumor typesG3 anemiaG3 neutropeniaG4 thrombocytopeniaIA/IBMurine double minute
2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.Peer-Reviewed Original ResearchConceptsAdvanced biliary tract carcinomaPhase I clinical trialPhase I unitABC patientsAdvanced biliary tract cancerMolecular characterisation of tumoursClinical outcomes of patientsClinical benefit rateBiliary tract carcinomaBiliary tract cancerComprehensive molecular profilingPhase I trialOutcomes of patientsCharacterisation of tumoursStable diseaseI unitsAdvanced diseaseI trialBenefit rateTargeted therapyTreatment detailsTrial discontinuationExceptional respondersPTEN lossClinical outcomes
2012
Significance of CEACAM6 expression in biliary tract carcinoma.
Rocha F, Torres J, Chou J, Katabi N, Gönen M, DeMatteo R, Fong Y, Allen P, D'Angelica M, Klimstra D, Jarnagin W. Significance of CEACAM6 expression in biliary tract carcinoma. Journal Of Clinical Oncology 2012, 30: 207-207. DOI: 10.1200/jco.2012.30.4_suppl.207.Peer-Reviewed Original ResearchDisease-specific survivalBile duct carcinomaCEACAM6 expressionDuct carcinomaTissue microarrayVascular invasionIntrahepatic cholangiocarcinomaAssociated with disease-specific survivalCases of bile duct carcinomaParaffin-embedded surgical specimensAssociated with age >Marker of poor outcomeAssociated with poor prognosisBiliary tract carcinomaPositive lymph nodesControl tissuesHigher T stageKaplan-Meier methodMultivariable proportional hazards regressionLog-rank testPredictors of survivalProportional hazards regressionHilar tumorsR0 resectionIntrahepatic tumors
2000
The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma.
Dillon DA, Johnson CC, Topazian MD, Tallini G, Rimm DL, Costa JC. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma. The Cancer Journal 2000, 6: 294-301. PMID: 11079168.Peer-Reviewed Original ResearchConceptsFine needle aspiratesBile duct brushingsCytologic diagnosisPositive predictive valueCommon bile duct brushingsDuct brushingsPancreatobiliary carcinomaPredictive valueMutation patternsBiliary tract carcinomaPrevious retrospective studyAvailable clinical informationConsecutive clinical specimensDefinitive cytologic diagnosisPolymerase chain reaction/single-strand conformation polymorphism analysisRoutine cytologic diagnosisPositive cytologyRetrospective studySuspicious morphologyCytologic evaluationSuspicious cytologyPancreatobiliary tractClinical informationMorphologic diagnosisNeoplastic cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply